300,000 Shares in GSK plc (NYSE:GSK) Bought by Vestal Point Capital LP

Vestal Point Capital LP purchased a new position in GSK plc (NYSE:GSK) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 300,000 shares of the pharmaceutical company’s stock, valued at approximately $12,264,000. GSK makes up approximately 0.9% of Vestal Point Capital LP’s portfolio, making the stock its 28th biggest holding.

Other institutional investors have also modified their holdings of the company. FMR LLC grew its holdings in shares of GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after acquiring an additional 2,224,345 shares in the last quarter. Primecap Management Co. CA grew its stake in GSK by 13.9% in the second quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company’s stock valued at $558,689,000 after purchasing an additional 1,773,020 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of GSK during the 2nd quarter worth approximately $52,487,000. Fisher Asset Management LLC raised its stake in shares of GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after purchasing an additional 870,449 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of GSK by 33.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,256,320 shares of the pharmaceutical company’s stock valued at $86,875,000 after buying an additional 569,614 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Trading Up 0.9 %

Shares of GSK stock opened at $34.33 on Friday. GSK plc has a 12-month low of $32.83 and a 12-month high of $45.92. The firm has a 50 day moving average price of $37.42 and a two-hundred day moving average price of $40.09. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The company has a market capitalization of $71.15 billion, a PE ratio of 22.29, a price-to-earnings-growth ratio of 1.31 and a beta of 0.66.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be paid a $0.3928 dividend. The ex-dividend date of this dividend is Friday, November 15th. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a yield of 4.58%. GSK’s payout ratio is 99.35%.

Insider Buying and Selling at GSK

In other GSK news, major shareholder Plc Gsk acquired 2,791,930 shares of the business’s stock in a transaction on Friday, September 27th. The stock was purchased at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the acquisition, the insider now directly owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. This trade represents a 19.97 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 10.00% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on GSK. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Barclays raised shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Argus upgraded GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and dropped their price objective for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Finally, Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Seven investment analysts have rated the stock with a hold rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.